Screener / SEC EDGAR /CIK 0001756262 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Devices

TransMedics Group, Inc. TMDX

We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. 10-K, Item 1

Headquarters
Andover, MA
CEO
Waleed H. Hassanein
Next results
around Feb 23, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $605.5M through the costs to a net profit of $190.3M · income statement of the 10-K

18% operating margin
Revenue to Gross profit: $362.8MRevenue to Cost of revenue: $242.7MGross profit to Operating profit: $108.6MGross profit to Operating expenses: $254.2MOperating profit to Net profit: $108.6MOther income to Net profit: $81.7MOperating expenses to R&D: $69.1MOperating expenses to SG&A: $185.2M Revenue: $605.5M REVENUE $605.5M +37% Y/Y Gross profit: $362.8M · 60% margin GROSS PROFIT $362.8M 60% margin · +38% Y/Y Cost of revenue: $242.7M · 40% of revenue COST OF REVENUE $242.7M 40% of revenue Operating profit: $108.6M · 18% margin OPERATING PROFIT $108.6M 18% margin · +190% Y/Y Other income: $81.7M · 13% of revenue OTHER INCOME $81.7M 13% of revenue Operating expenses: $254.2M · 42% of revenue OPERATING EXPENSES $254.2M 42% of revenue Net profit: $190.3M · 31% margin NET PROFIT $190.3M 31% margin · +437% Y/Y R&D: $69.1M · 11% of revenue R&D $69.1M 11% of revenue SG&A: $185.2M · 31% of revenue SG&A $185.2M 31% of revenue
Gross profit $362.8M 60% margin · +38% Y/Y
Operating profit $108.6M 18% margin · +190% Y/Y
Net profit $190.3M 31% margin · +437% Y/Y
The full income statement, year by year

TMDX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 37.1%, above 86% of 154 peers (their median 10.4%) REVENUE GROWTH 37.1% · above 86% Gross margin: 58.6%, above 42% of 107 peers (their median 63.8%) GROSS MARGIN 58.6% · above 42% Operating margin: 11.9%, above 58% of 138 peers (their median 9.8%) OPERATING MARGIN 11.9% · above 58% Net margin: 19.9%, above 85% of 153 peers (their median 6.7%) NET MARGIN 19.9% · above 85% FCF margin: 6.1%, above 38% of 144 peers (their median 10.1%) FCF MARGIN 6.1% · above 38% Return on capital: 34.9%, above 97% of 89 peers (their median 9.0%) RETURN ON CAPITAL 34.9% · above 97%
TMDX Peer median Below the median

What changed

17 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 24, 2026 against Feb 27, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Material weakness in internal control
    “Based on the evaluation of our disclosure controls and procedures as of December 31, 2025, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective due to the material weakness in internal control over financial reporting described below.”
  • Receivables -13.8% ($97.7M to $84.3M) vs revenue +37.1% ($441.5M to $605.5M), -50.9 pts apart
9 more checks with nothing to note
  • Cash from operations $192.8M vs net income $190.3M (FY ending Dec 31, 2025)
  • Inventory +5.0% ($46.6M to $48.9M) vs revenue +37.1% ($441.5M to $605.5M), -32.1 pts apart
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue Recognition
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

17 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 17 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    In order to manufacture the OCS in quantities sufficient to meet our anticipated commercial opportunity, we will need to continue to increase our manufacturing capabilities and retain third parties to sterilize our products. We anticipate that our new
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Inventory levels in excess of customer demand may result in a portion of our inventory becoming obsolete or expiring, as well as inventory write-downs or write-offs. Conversely, if we underestimate customer demand for our products or our own requirements
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    As part of our services offered under our NOP, we have acquired a fleet of fixed-wing aircraft. All of the aircraft we currently operate are standardized variants of a certificated model produced by a single manufacturer. Parts and services from this manufacturer
  4. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    We may experience disruptions to our business as a result of the relocation of our headquarters and general expansion of our operations. We may experience disruptions as we continue to expand our operations and facilities and execute on our growth strategy. In January 2026, we entered into a lease agreement with the intent to move our…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$93.5M$241.6M$441.5M$605.5M
Net income−$36.2M−$25.0M$35.5M$190.3M
Operating cash flow−$45.8M−$13.0M$48.8M$192.8M
Free cash flow−$57.7M−$164.9M−$80.9M$133.6M

Revenue, FY2018 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$605.5M ▲ 37.1% in FY2025

FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

TransMedics Group, Inc., Andover, MA · from the 10-K filed Feb 24, 2026

We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. As such, the OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment.

Headquarters
Andover, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
MA

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.